Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma

European Journal of Cancer

Volumn 34, Issue 5, 1998, Pages 718-723

  Fontanini, G ^b   Boldrini, L ^b   Vignati, S ^b   Chine S ^b   Basolo, F ^b   Silvestri, V ^b   Lucchi, M ^a   Mussi, A ^a   Angeletti, C A ^a   Bevilacqua, G ^b  

^a UNIVERSITY OF PISA   (Italy)

^b NONE

Author keywords

Angiogenesis; bc12; p53; VEGF

Indexed keywords

PROTEIN P53; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BLOOD FLOW;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOKINES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032055269     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10145-9     Document Type: Article

References (33)

1. 1. Murakami MS, Strobel ME, Vanderwoude GF. Cell cycle regulation oncogenes and antineoplastic drugs. In Mendelsohn J, Mowley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia, WB Saunders, 1995, 3-17.
2. 2. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. In De Vita Jr VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology 1996. Philadelphia, Lippincott-Raven, 1996, 167-190.
3. 3. Slebos RJC, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1991, 324, 1084-1090.
4. 4. Quinlan DC, Davidson AS, Summers CL, Warden HE, Doshi HM. Accumulation of p53 correlates with a poor prognosis in human lung cancer. Cancer Res 1992, 52, 4828-4831.
5. 5. Harpole DH, Herdon JH, Wolfe WG, Iglehart JD, Marks JRA. Prognostic model of recurrence and death in Stage I non-small cell lung cancer utilizing presentation, and oncoprotein expression. Cancer Res 1995, 55, 51-56.
6. 6. Tateishi M, Ishida T, Mitsudomi T, Kanero S, Sugimachi K. Prognostic value of c-erb-B protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991, 27A, 1372-1375.
7. 7. Macchiarini P, Fontanini G, Hardin JM, Squartini F, Angeletti A. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992, 340(1), 45-46.
8. 8. Fontanini G, Bigini D, Vignati S, et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Path 1995, 177, 57-63.
9. 9. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non small-cell lung cancer. J Natl Cancer Inst 1997, 89, 881-885.
10. 10. Dameron KM, Volpert OG, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265, 1582-1584.
11. 11. Kieser A, Weich Ha, Brandner G, Marme' D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994, 9, 964-969.
12. 12. Fontanini G, Vignati S, Lucchi M, et al. Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 1997, 75, 1295-1301.
13. 13. Fontanini G, Vignati S, Bigini D, et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995, 72, 1003-1007.
14. 14. World Health Organization. The World Health Organization. Histological typing of lung tumours. Am J Clin Pathol 1982, 77, 123-136.
15. 15. American Joint Committee on Cancer. Manual for a Staging of Cancer, 4th edition, 1992, 115-122.
16. 16. Wizigmann-Voos S, Breier G, Risau W, Plate KH. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 1995, 55, 1358-1364.
17. 17. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complex). J Histochem Cytochem 1984, 32, 219-222.
18. 18. Pezzella F, Jones M, Ralfkier E, Ersbøl J, Gatter KC, Mason DJ. Evaluation of bcl2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. Br J Cancer 1992, 65, 87-89.
19. 19. Fontanini G, Bigini D, Vignati S, et al. p53 expression in non small cell lung cancer: clinical and biological correlations. Anti-cancer Res 1993, 13, 737-742.
20. 20. Harpole DH, Richards WG, Herndon JE, Sugarbaker DJ. Angiogenesis and molecular biological substaging in patients with Stage I non-small cell lung cancer. Ann Thorac Surg 1996, 61, 1470-1476.
21. 21. Giatromanolaki A, Koukourakis M, O'Byrne K, et al. Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 1996, 179, 80-88.
22. 22. Angeletti CA, Lucchi M, Fontanini G, et al. Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (Stage IIIA-N2). Cancer 1996, 78, 409-415.
23. 23. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast. Cancer Res Treat 1995, 36, 127-137.
24. 24. Shibuya M. Role of VEGF-FLT receptor system in normal and tumor angiogenesis. Adv Cancer Res 1995, 67, 281-316.
25. 25. Maeda K, Chung Y, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77, 858-863.
26. 26. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana C, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal type gastric cancer. Clin Cancer Res 1996, 2, 1679-1684.
27. 27. Takahashi Y, Mai M, Kitadai Y, Bucana C, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res 1995, 55, 3964-3968.
28. 28. Ohta Y, Endo Y, Tanaka M, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996, 2, 1411-1416.
29. 29. Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non small-cell lung carcinoma. N Engl J Med 1993, 329, 690-694.
30. 30. Johnson, R. E. Molecular biology of lung cancer. In Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia, WB Saunders, 1995, 317-339.
31. 31. Mukhopadhyay D, Tsiokas L, Sukhatme V. Wild-type P53 and v-Src opposing influence on human vascular endothelial growth factor gene expression. Cancer Res 1995, 57, 6161-6165.
32. 32. Ryan JJ, Prochownik E, Gottlieb, CA, et al. c-myc and bcl2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 1994, 91, 5878-5882.
33. 33. Hennet T, Bertoni G, Richter C, Peterhans E. Expression of bcl2 protein enhances the survival of mouse fibrosarcoid cells in tumor necrosis factor-mediated cytotoxicity. Cancer Res 1993, 53, 1456-1460.